CLAIM CARD
The null effect direction designation for this outcome class in the synthesis reflects the complexity of aggregating heterogeneous endpoint responses across included studies. By contrast, the highly significant P < 0.00001 findings for multiple comparisons suggest that certain cardiac biomarker pathways are more consistently modulated by SGLT2 inhibitors than others. These within-corpus tensions underscore the need for further investigation into which specific cardiac function domains show the most reliable treatment responses.
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025